Karyopharm Therapeutics | DEBITO





DEBITO Cambiamento Data
AbbVie USD 1000K 70.48B 2025-09
Abbott USD 12.94B 496M 2025-09
Amgen USD 54.59B 1.62B 2025-09
AstraZeneca USD 32.63B 207M 2025-09
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Eli Lilly USD 42.51B 2.6B 2025-09
Enanta Pharmaceuticals USD 1.35M 0 2024-12
GlaxoSmithKline GBP 17.75B 396M 2025-09
Incyte USD 41.27M 1.14M 2025-09
J&J USD 45.8B 4.97B 2025-09
Karyopharm Therapeutics USD 264.09M 39.31M 2024-09
MacroGenics USD 37.01M 238K 2025-09
Merck USD 41.37B 5.97B 2025-09
Nektar Therapeutics USD 0 0 2022-06
Novartis USD 32.64B 1.37B 2025-06
Novartis USD 32.02B 615M 2025-09
Pfizer USD 60.85B 78M 2025-09
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Roche Holding CHF 33.03B 1.41B 2025-06
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.85T 208B 2025-12
Tectonic Therapeutic USD 876K 115K 2024-12
TG Therapeutics USD 245.34M 8.38M 2025-09
Ultragenyx Pharmaceutical USD 36.3M 1.98M 2025-06
Xencor USD 67.93M 86.45M 2025-06


Karyopharm Therapeutics DEBITO - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.